2026-08-18Bullish
+5.96%24 hours changeThe stock rebounded due to an oversold mean-reversion bounce and valuation re-rating following an aggressive post-earnings selloff.
read the report →Insulet Corporation is a medical device manufacturer that develops, manufactures, and markets the Omnipod continuous automated insulin delivery platform.
stitched from the price window carried by each report
The stock rebounded due to an oversold mean-reversion bounce and valuation re-rating following an aggressive post-earnings selloff.
read the report →Insulet lowered full-year 2026 revenue guidance due to high customer churn during Type 2 diabetes patient onboarding.
read the report →Insulet lowered its 2026 revenue guidance due to high patient attrition and low utilization among Type 2 diabetes users.
read the report →